Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Eli Lilly and Company (LLY - Analyst Report) recently presented data on Cialis at the annual European Association of Urology (EAU) Congress.

Results from a 26-week, randomized, double-blind, placebo-controlled study showed that once daily Cialis (5 mg) plus Merck’s (MRK - Analyst Report) Proscar (finasteride) improved scores significantly on the International Prostate Symptom Score (IPSS) in men with lower urinary tract symptoms of benign prostatic hyperplasia (LUTS/BPH) and enlarged prostates compared to placebo/Proscar alone.

Erectile function scores were also better in the Cialis plus Proscar arm compared to placebo/Proscar alone in men suffering from both LUTS/BPH and erectile dysfunction.

Cialis, which is approved for the treatment of erectile dysfunction as well as the treatment of BPH, posted sales of $1.93 billion in 2012. Cialis’ main competitors in the ED market include Viagra and Levitra.

The BPH market is also pretty crowded with products like Avodart, Jalyn, Uroxatral and Rapaflo among others.

Eli Lilly currently carries a Zacks Rank #3 (Hold). The biggest near-term challenge for Eli Lilly will be to replace the revenues that will be lost to generic competition now that Zyprexa has lost US and EU exclusivity. The generic threat will continue to pose challenges for Eli Lilly with Cymbalta slated to lose patent protection in late 2013 and Evista in 2014.

On the flip side, the Animal Health business and the diabetes franchise should provide some downside support. We are also pleased to see Eli Lilly pursuing small acquisitions and in-licensing deals to boost its pipeline.

Currently, large-cap companies like Novo Nordisk (NVO - Analyst Report) carry a Zacks Rank #2 (Buy). Avanir Pharmaceuticals, Inc. (AVNR - Snapshot Report) also looks attractive with a Zacks Rank #2.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%